KUNMING, China, July 23 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (“China Shenghuo,” “the Company”) (Amex: KUN), a leading specialty pharmaceutical company engaged in researching, developing, manufacturing and marketing Sanchi-based medicinal products in the People’s Republic of China (“PRC”), will ring the opening bell of the American Stock Exchange on Tuesday, July 24, 2007.
Mr. Feng Lan, President, and Ms. Qionghua Gao, Chief Financial Officer, will preside over the opening bell ceremony.
“We are very proud to be one of the select Chinese pharmaceutical manufacturers listed on a major overseas exchange,” said Mr. Gui Hua Lan, Chairman and Chief Executive Officer of China Shenghuo. “Access to the global capital market and a more visible public profile will help drive our plan for sustained growth as we expand into international markets and increase our selection of pharmaceutical and cosmetic products within China.”
China Shenghuo began trading on AMEX with an opening price of $3.50 per share on June 14.
“We are continually seeking new profit drivers through constant research on plant-based drugs and expansion into the over-the-counter market,” said Mr. Feng Lan, President of China Shenghuo. “We are excited to partner with AMEX as we pursue that strategy.”
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. (“China Shenghuo” or “the Company”) is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd (“Kunming Shenghuo”), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine into 1,650 hospitals and 1,500 drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains certain “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors include, but are not limited to, the company’s reliance on one supplier for Sanchi, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of the company’s intellectual property rights, market acceptance of the company’s products, changes in the laws of the People’s Republic of China that affect the company’s operations, the company’s ability to obtain all necessary government certifications and/or licenses to conduct the company’s business, the cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company’s operations and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
